International Vaccine Institute inks Indian alliances

Nonprofit International Vaccine Institute (IVI) has inked partnerships with Indian agencies as part of its drive to deepen ties to the country. IVI wants to work more closely with India on the clinical development and manufacturing of new vaccines. Feature

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.